Urgent hybrid palliation for interrupted aortic arch in a preterm infant

Romans, Ryan A.; Armstrong, Aimee K.; Aiyagari, Ranjit

doi:10.1017/s1047951117001871

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hybrid palliation has also been used as a bailout strategy in high-risk non-HLHS patients such as those with an interrupted aortic arch [40]. Others have used this palliation strategy as a bridge to transplantation in non-HLHS patients [41].…”

Section: Other Hybrid Variationsmentioning

confidence: 99%

The Evolution of Therapeutic Strategies: Niche Apportionment for Hybrid Palliation

Haller

Caldarone

2018

The Annals of Thoracic Surgery

View full text Add to dashboard Cite

Section: Other Hybrid Variationsmentioning

confidence: 99%

The Evolution of Therapeutic Strategies: Niche Apportionment for Hybrid Palliation

Haller

Caldarone

2018

The Annals of Thoracic Surgery

View full text Add to dashboard Cite

Use of Hybrid Stage I to Stratify Between Single Ventricle Palliation and Biventricular Repair

Smith,

Zampi,

Balasubramanian

et al. 2024

World J Pediatr Congenit Heart Surg

View full text Add to dashboard Cite

Background: Hybrid stage I palliation (HS1P) has been utilized for patients with single ventricle (SV) congenital heart disease (CHD). To date, reports on the use of HS1P for other indications including biventricular (BiV) CHD have been limited. Methods: We performed a single-center retrospective cohort study of patients who underwent HS1P with an anticipated physiologic outcome of BiV repair, or with an undetermined SV versus BiV outcome. Patient characteristics and outcomes from birth through definitive repair or palliation were collected and reported with descriptive statistics. Results: Nineteen patients underwent HS1P with anticipated BiV repair. Extracardiac and intracardiac risk factors (ICRF) were common. Ultimately, 13 (68%) patients underwent BiV repair, 1 (5%) underwent SV palliation, and 5 (26%) died prior to further palliation or repair. Resolution of ICRF tracked with BiV outcome (6/6, 100%), persistence of ICRF tracked with SV outcome or death (3/3, 100%). Twenty patients underwent HS1P with an undetermined outcome. Ultimately, 13 (65%) underwent BiV repair, 6 (30%) underwent SV palliation, and 1 (5%) underwent transplant. There were no deaths. Intracardiac risk factors were present in 15 of 20 patients (75%); BiV repair only occurred when all ICRF resolved (67%). Post-HS1P complications and reinterventions occurred frequently in both groups, through all phases of care. Conclusions: Hybrid stage 1 palliation can be used to defer BiV repair and to delay decision between SV palliation and BiV repair. Resolution of ICRF was associated with ultimate outcome. In this high-risk group, complications are common, and mortality especially in the marginal BiV patient is high.

show abstract